Related Experiment Videos
Newly identified U4/U6 snRNP-binding proteins by serum autoantibodies from a patient with systemic sclerosis
1Department of Medicine, University of Pittsburgh School of Medicine, PA 15261.
Abstract:
We found serum autoantibodies directed against the proteins binding exclusively to U4/U6 of Sm small nuclear ribonucleoprotein particle (snRNP) in serum from a patient (MaS) with systemic sclerosis. Their specificity, called anti-MaS, is distinct from that of known antibodies against U snRNP. The U4 and U6 small nuclear RNA from a 32P-labeled HeLa cell extract and five proteins with Mr 150,000, 120,000, 80,000, 36,000, and 34,000, in addition to Sm core proteins (B, B', D, E, F, and G) from an [35S] methionine-labeled extract, were immunoprecipitated by anti-MaS in isotonic solution. However, the Sm core proteins and U4 and U6 small nuclear RNA were separated from the protein-A-Sepharose facilitated MaS immunoprecipitate by incubation in a solution containing 500 mM NaCl. In immunoblots, anti-MaS antibodies reacted with one protein of Mr 150,000 from a HeLa cell nuclear extract that was fractionated by SDS-PAGE and transferred to a nitrocellulose sheet. The monospecific immunoaffinity purified antibody eluted from the immunoblot band immunoprecipitated U4 and U6 small nuclear RNA and reblotted the protein with Mr 150,000. These data indicate that anti-MaS antibodies recognize at least one antigenic protein that binds exclusively to the U4/U6 snRNP.
Insights
Researchers identified novel serum autoantibodies, anti-MaS, targeting proteins unique to U4/U6 small nuclear ribonucleoprotein particles (snRNPs). These antibodies are distinct from previously known anti-U snRNP antibodies, offering new insights into autoimmune diseases.
Area of Science:
- Immunology
- Molecular Biology
- Autoimmunity
Background:
- Systemic sclerosis is an autoimmune disease characterized by diverse autoantibodies.
- Small nuclear ribonucleoprotein particles (snRNPs) are crucial for RNA splicing and are targets of autoimmune responses.
Observation:
- Serum autoantibodies, termed anti-MaS, were identified in a patient with systemic sclerosis.
- These autoantibodies specifically targeted proteins binding exclusively to U4/U6 snRNP components.
Findings:
- Anti-MaS antibodies immunoprecipitated U4/U6 snRNP-associated proteins, including a distinct 150,000 Mr protein.
- The antibodies did not precipitate Sm core proteins or U4/U6 snRNA under high salt conditions, indicating specificity.
- Purified anti-MaS antibodies confirmed recognition of the 150,000 Mr protein exclusively associated with U4/U6 snRNP.
Implications:
- The anti-MaS autoantibody specificity is distinct from known anti-U snRNP antibodies.
- Identification of anti-MaS antibodies provides a novel biomarker for systemic sclerosis.
- These findings advance the understanding of autoimmune targets within snRNP complexes.